Clinicopathologic, genomic and protein expression characterization of 356 ROS1 fusion driven solid tumors cases.
Aged
B7-H1 Antigen
/ metabolism
Biomarkers, Tumor
/ genetics
Carcinoma, Non-Small-Cell Lung
/ genetics
Cohort Studies
Databases, Genetic
Female
Genomics
Humans
Immunohistochemistry
Lung Neoplasms
/ genetics
Male
Middle Aged
Mutation
Oncogene Fusion
/ genetics
Protein-Tyrosine Kinases
/ antagonists & inhibitors
Proto-Oncogene Proteins
/ antagonists & inhibitors
Retrospective Studies
CGP
ROS1 fusion
solid tumors
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
01 04 2021
01 04 2021
Historique:
received:
09
10
2020
revised:
16
11
2020
accepted:
01
12
2020
pubmed:
19
12
2020
medline:
6
8
2021
entrez:
18
12
2020
Statut:
ppublish
Résumé
Based on the approvals of crizotinib and entrectinib by the Food and Drug Administration for the treatment of ROS1 positive nonsmall cell lung cancer (NSCLC), we sought to examine the mutational profile of a variety of solid tumors (excluding sarcomas) with ROS1 fusions that underwent comprehensive genomic profiling. A review of our database was performed to extract all nonsarcoma patients with ROS1 fusions that were discovered by the hybrid capture-based DNA only sequencing assays. We examined the coalterations representing potentially targetable biomarkers, resistance alterations and other alterations in these cases. In addition, we examined the histologic characteristics and protein expression with immunohistochemistry (IHC). From a series of clinically advanced nonsarcoma solid tumors, 356 unique cases with ROS1 fusions included 275 (77.2%) NSCLC and 81 (22.8%) non-NSCLC. Ten novel ROS1 fusions were discovered. Importantly, the NSCLC ROS1 fusion
Substances chimiques
B7-H1 Antigen
0
Biomarkers, Tumor
0
CD274 protein, human
0
Proto-Oncogene Proteins
0
Protein-Tyrosine Kinases
EC 2.7.10.1
ROS1 protein, human
EC 2.7.10.1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1778-1788Informations de copyright
© 2020 UICC.
Références
Davies KD, Doebele RC. Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res. 2013;19:4040-4045.
Birchmeier C, Sharma S, Wigler M. Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A. 1987;84:9270-9274.
Lin JJ, Shaw AT. Recent advances in targeting ROS1 in lung cancer. J Thorac Oncol. 2017;12:1611-1625.
Shaw AT, Solomon BJ. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2015;372:683-684.
FDA. FDA expands use of Xalkori to treat rare form of advanced non-small cell lung cancer. https://www.fda.gov/news-events/press-announcements/fda-expands-use-xalkori-treat-rare-form-advanced-non-small-cell-lung-cancer. Accessed June 2020.
FDA. FDA approves entrectinib for NTRK solid tumors and ROS-1 NSCLC. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-entrectinib-ntrk-solid-tumors-and-ros-1-nsclc. Accessed June 2020.
Drilon A, Siena S, Dziadziuszko R, et al. Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials. Lancet Oncol. 2020;21:261-270.
Bergethon K, Shaw AT, Ou SH, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol. 2012;30:863-870.
Li C, Fang R, Sun Y, et al. Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers. PLoS One. 2011;6:e28204.
Gainor JF, Shaw AT. Novel targets in non-small cell lung cancer: ROS1 and RET fusions. Oncologist. 2013;18:865-875.
Lin JJ, Ritterhouse LL, Ali SM, et al. ROS1 fusions rarely overlap with other oncogenic drivers in non-small cell lung cancer. J Thorac Oncol. 2017;12:872-877.
Frampton GM, Fichtenholtz A, Otto GA, et al. Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing. Nat Biotechnol. 2013;31:1023-1031.
Chalmers ZR, Connelly CF, Fabrizio D, et al. Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden. Genome Med. 2017;9:34.
Trabucco SE, Gowen K, Maund SL, et al. A novel next-generation sequencing approach to detecting microsatellite instability and pan-tumor characterization of 1000 microsatellite instability-high cases in 67,000 patient samples. J Mol Diagn. 2019;21:1053-1066.
Zehir A, Benayed R, Shah RH, et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med. 2017;23:703-713.
Connelly CF, Carrot-Zhang J, Stephens PJ, Frampton GM. Abstract 1227: somatic genome alterations in cancer as compared to inferred patient ancestry. Cancer Res. 2018;78:1227.
DAKO. PD-L1 IHC 22C3 pharmDx Interpretation Manual - NSCLC. https://www.agilent.com/cs/library/usermanuals/public/29158_pd-l1-ihc-22C3-pharmdx-nsclc-interpretation-manual.pdf. Accessed December 2019.
Goeman JJ, Solari A. Multiple hypothesis testing in genomics. Stat Med. 2014;33:1946-1978.
NCCN. NCCN Clinical Practice Guidelines in Oncology, Non-Small Cell Lung Cancer. Version 5.2019, vol. 2019. https://www.nccn.org/professionals/physician_gls/pdf/nscl_blocks.pdf. Accessed December 2019.
Guisier F, Piton N, Salaun M, Thiberville L. ROS1-rearranged NSCLC with secondary resistance mutation: case report and current perspectives. Clin Lung Cancer. 2019;20:e593-e596.
Dziadziuszko R, Le AT, Wrona A, et al. An activating KIT mutation induces crizotinib resistance in ROS1-positive lung cancer. J Thorac Oncol. 2016;11:1273-1281.
Cargnelutti M, Corso S, Pergolizzi M, et al. Activation of RAS family members confers resistance to ROS1 targeting drugs. Oncotarget. 2015;6:5182-5194.
Zhu Y-C, Lin X-P, Li X-F, et al. Concurrent ROS1 gene rearrangement and KRAS mutation in lung adenocarcinoma: a case report and literature review. Thorac Cancer. 2018;9:159-163.
Roys A, Chang X, Liu Y, Xu X, Wu Y, Zuo D. Resistance mechanisms and potent-targeted therapies of ROS1-positive lung cancer. Cancer Chemother Pharmacol. 2019;84:679-688.
Sato H, Schoenfeld AJ, Siau E, et al. MAPK pathway alterations correlate with poor survival and drive resistance to therapy in patients with lung cancers driven by ROS1 fusions. Clin Cancer Res. 2020;26(12):2932-2945.
Uguen A, De Braekeleer M. ROS1 fusions in cancer: a review. Future Oncol. 2016;12:1911-1928.
Rimkunas VM, Crosby KE, Li D, et al. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion. Clin Cancer Res. 2012;18:4449-4457.
Couts KL, McCoach CE, Murphy D, et al. Acral lentiginous melanoma harboring a ROS1 gene fusion with clinical response to entrectinib. JCO Precis Oncol. 2017;1:1-7.
Davare MA, Henderson JJ, Agarwal A, et al. Rare but recurrent ROS1 fusions resulting from chromosome 6q22 microdeletions are targetable oncogenes in glioma. Clin Cancer Res. 2018;24:6471-6482.
Huang RSP, Haberberger J, Severson E, et al. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases. Mod Pathol. 2020. Online ahead of print. PMID: 32884129.
Huang RSP, Li X, Haberberger J, et al. Biomarkers in breast cancer: an integrated analysis of comprehensive genomic profiling and PD-L1 immunohistochemistry biomarkers in 312 patients with breast cancer. Oncologist. 2020;25:943-953.
Chen R, Zhao W-Q, Fang C, Yang X, Ji M. Histone methyltransferase SETD2: a potential tumor suppressor in solid cancers. J Cancer. 2020;11:3349-3356.